Chemical modification of antibodies and antigens

Abstract: There is described a method for the chemical modification of antibodies and/or antigens in order to minimise sample interference in immunoassays, an immunoassay method in which chemically modified antibodies and/or antigens are employed, the use of chemically modified antibodies and/or antigens in an immunoassay and a kit for assaying biological specimens which comprises the chemically modified antibodies and/or antigens.

Description: This invention relates to an immunoassay method in which chemically modified antibodies are employed in order to minimise sample interference, to the use of the chemically modified antibodies in an immunoassay and to a kit for assaying biological specimens which comprises the chemically modified antibodies. Sample interference in immunoassays involves deleterious interactions between specific components of immunoassays and interfering species in samples and is a well documented phenomenon. References to sample interference include (1) Levinson S., "Heterophilic antibodies and their role in immunoassay interference"; J. Clin. Immunoassay, 1992, 15 , 108-115 and (2) Maxey K. M., Krishna R. M and Birkmeir J., "Interference in Enzyme Immunoassays"; J. Clin. Immunoassay, 1992 15 , 116-120. Much of this interference can be attributed to the presence of species within samples that cross-link specific immunoassay components. Routinely this is caused by antibodies or other sample components that are directed against either (a) structural elements of the immunoglobulins of the immunoassay or (b) structural elements of native, recombinant or synthetic antigens. Immunoglobulins are constructed from two heavy chains each consisting of three constant regions (CH-1, CH-2 and CH-3) and a variable region (VH). These are associated with two light chains each consisting of a constant region (CL) and a variable region (VL). There are also structural variants of immunoglobulin heavy and light chains termed isotypes - see for example Vlug A. and Van Remortal P., "The structure and function of human IgG subclasses"; European Clinical Lab., 1989, 8 , 26-33. An interfering sample may show reactivity against one isotype but not another. Other interfering samples may show reactivity across isotypes. A significant proportion, although not all, of the interfering anti-antibody components are directed against the Fc region (CH2-CH3) of the assay specific immunoglobulins. Interference can also occur when labelled and unlabelled assay specific species, where one or more of these is the antigen, are cross-linked by an interfering species. Blocking of interference has been achieved in the past by addition of quantities of immunoglobulin containing sera from different species or purified immunoglobulins or aggregated immunoglobulins. This has been described in US Patent No 4914040 to Boehringer Mannheim issued 1990 and entitled "Reagent and method for determination of a polyvalent substance using an immunoaggregate. Reduction of the interference has also been achieved by removal of the Fc fragment from one or more of the assay specific immunoglobulins and also by blocking assay specific antibody with anti FC antibody as described in European Patent Publication No. 566205A. It has been reported that rheumatoid factor and other interfering species are predominantly reactive with the CH-2 and CH-3 regions on immunoglobulin heavy chains - see for example Williams R. C., Malone C. and Solomon A., "Conformational dependency of human IgG heavy chain-associated Gm allotypes"; Mol. Immunol., 1993, 30 , (4), 341-351. The existance of species reactive with the CH1 region of immunoglobulin heavy chains is also known - see for example Aguado M. T., Balderas R. S., Rubin R. L., Duchosal R. K., Kofler R., Birshtein B. K., Secher D. S., Dixon F. J. and Theofilopoulos A. N., "Specificity and molecular characteristics of monoclonal IgM rheumatoid factors from arthritic and non-arthritic mice"; J. Immunol., 1987, 139 , 1080-1087. The presence of these factors in sample sera can cause incorrect antigen concentration determinations in immunoassays. Removal of the Fc from assay specific immunoglobulins will therefore not prevent factors reactive with the CH-1 region from binding. According to the present invention we provide a method for the immunoassay of a biological specimen as defined in claim 1. Further according to the present invention we provide the use in a method for the immunoassay of a biological specimen of a modified antibody and/or fragment of an antibody as defined in claim 2. Further according to the present invention we provide a kit useful in an immunoassay which comprises an antibody and/or fragment of an antibody as defined in claim 3. The chemical modification of specific amino acid residues in the immunoglobulin enables blocking or reduction of the interactions mentioned above to be achieved. Suitably the antibody and/or fragment (hereinafter referred to as the reagent particle) is chemically treated to modify the charge and/or structural properties of one or more of the group of amino acids concerned ie arginine, histidine, lysine, threonine and tyrosine so that recognition by the reagent particle of an interfering antibody is no longer possible. Suitably the active sites on the reagent particle which are targeted for modification of amino acids are those areas to which an interfering amino acid could bind to a significant extent. The target regions of the reagent particle include the "constant" regions of antibodies. During the modification method, arginine, histidine, lysine, threonine and tyrosine moieties located on a reagent particle elsewhere than at active sites are protected in a manner suitable to prevent any significant modification of them from occurring. Any suitable chemical modification of the amino acid moieties concerned on the reagent particle may be used in the modification method of the invention. The preferred modification technique in any instance will depend upon the amino acid to be modified. Chemical compounds which can be used to modify reagent particles include compounds having the structure : R - O - CO - X where R can be any of a wide range of groups including alkyl, aryl and pyridyl ; and X is a leaving group such as pyrocarbonate - O - CO - OR , a halogen group, particularly a chloride or a bromide or a mixed acid anhydride such as - O - CO - R' , where R' can be any one of a wide range of alternatives (compounds of this structure are particularly useful for the modification of histidine or lysine moeties) ; Alkyl halides ; and Compounds having the structures : Y - CR - CO -R ; R - CO - Y ; and R - NCO - Z where R is as before, having a wide range of possibilities ; Y is suitably an acid group, an activating ester group or a halogen group particularly chloride or bromide; and Z is a halogen group. . The chemical compound used in the modification method can also be a precursor of that used to effect the modification, ie a source of suitable radicals. An example of such a precursor is diazomethane. Specific compounds which can be used include N-benzyloxycarbonyloxy succinimide, N-(2-bromobenzyloxycarbonyloxy) succinimide, diphenylcarbamyl chloride and adamantyl fluoroformate. Compounds particularly suitable for the modification method of the invention in a wide range of instances are pyrocarbonates having the structure : R - O - CO - O - OC - O - R , where R can vary greatly, possible groups including aryl, alkyl and pyridyl. Particularly suitable pyrocarbonates include dimethylpyrocarbonate diethylpyrocarbonate and dipropylpyrocarbonate. Suitable conditions for the modification process of the invention depend on the reagent particle, the chemical modifier used, the amino acid group to be modified and its location in the reagent particle, ie the target region. Suitably the pH is selected to take account of the target site and the chemical reagent used to effect the modification. The temperature affects the specificity of the modification achieved and is suitably controlled to obtain suitable specificity. Greater specificities are achieved at lower temperatures. The invention is generally applicable to immunoassays including assays for TSH , Toxo IgG, Toxo IgM, Rubella and free hormone assays. The modified antibody in the kit of the invention is supplied as conjugate together with an enzyme marker such as horse radish peroxidase (HRP). The invention gives the advantage of reduced sample interference in the operation of immunoassays. The invention is illustrated by the following Examples and by the accompanying drawings wherein: Figure 1 is a block diagram illustrating the results of Example 2; and Figure 2 is a graph illustrating the results of Example 3. Example 1 A horseradish peroxidase conjugated anti-TSH antibody (anti-TSH-HRP) was pretreated with 34 mMolar diethylpyrocarbonate in 0.1 molar phosphate buffer at pH 6.0 for 30 minutes at room temperature. The thus pretreated and modified anti-TSH-HRP was then diluted to 0.42ug/ml in a phosphate buffer containing 1% w/v Bovine Serum Albumin.This was then incubated with a euthyroid serum known to contain an interfering species in immunoassay wells coated with a second anti- TSH antibody. Unmodified anti-TSH-HRP was included in the experiment as a control. The incubation was carried out for 30 minutes at 37°C on an "Amerlite" (TM) shaker incubator marketed by Kodak Clinical Diagnostics Limited (KCDL), Mandeville House, 62 The Broadway, Amersham, Buckinghamshire, HP7 0HJ, UK. After this the wells were washed and "Amerlite" Signal Generation Reagent (also marketed by KCDL) was added. The level of signal and data integration for each sample was determined on an "Amerlite" Analyser (also marketed by KCDL). The experiment was carried out generally in the manner described in the pack leaflet of the standard test for anti-TSH antibody marketed by KCDL. The results were as follows: TSH measured using unmodified antibody 9.37mIU/ml = Hypothyroid TSH measured using modified antibody 0.23mIU/ml = Euthyroid Example 2 This was carried out using experimental conditions which were identical with those of Example 1 save for the modification described hereafter. Example 1 was modified in that 29 known rheumatoid positive samples all known to be euthyroid were diluted 1 in 10 and assayed using either modified or unmodified anti-TSH-HRP antibody. The results are set out in Figure 1 which is a block diagram comparing the intensities of the light signals in Light Units for modified and unmodified samples. Figure 1 shows that the intensities of the interfering signals for the unmodified samples are significantly greater than those of the modified samples. Example 3 The preservation of the antigen binding capability of a modified anti-TSH-HRP antibody was demonstrated by incubating a range of concentrations of TSH in anti-TSH antibody coated wells in the presence of either a modified or an unmodified anti-TSH-HRP antibody. The quantity of TSH measured in each system was then determined from signal outputs after addition of "Amerlite" (TM) Signal Generation Reagent. Figure 2, which is a graph of signal intensity against TSH concentration in mIU/ml, compares the antigen binding capability of the modified and unmodified wells. It can be seen from Figure 2 that there is no significant difference between the antigen binding capabilities of the modified and unmodified antibodies.

Claims: A method for the immunoassay of a biological specimen which comprises a step in which there is used an antibody and/or a fragment of an antibody wherein at least one arginine, histidine, lysine, threonine or tyrosine amino acid moiety, located at an active site within the constant regions of said antibody and/or fragment thereof has been modified by chemical treatment in such a manner that recognition by the antibody and/or fragment thereof of an interfering antibody is substantially prevented; and during modification by chemical treatment, the arginine, histidine, lysine, threonine and tyrosine moieties present in the antibody and/or fragment thereof which are not in active sites were protected from reaction. The use in a method for the immunoassay of a biological specimen of a modified antibody and/or fragment of an antibody wherein: at least one arginine, histidine, lysine, threonine or tyrosine amino acid moiety, located at an active site within the constant regions of the antibody and/or fragment thereof has been modified by chemical treatment in such a manner that recognition by the antibody and/or fragment thereof of an interfering antibody is substantially prevented; and during modification by chemical treatment, the arginine, histidine, lysine, threonine and tyrosine moieties present in the antibody and/or fragment thereof which are not in active sites were protected from reaction. A kit useful in an immunoassay which comprises an antibody and/or fragment of an antibody wherein: at least one arginine, histidine, lysine, threonine or tyrosine amino acid moiety, located at an active site within the constant regions of the antibody and/or fragment thereof, has been modified by chemical treatment in such a manner that recognition by the antibody and/or fragment thereof of an interfering antibody is substantially prevented; and during modification by chemical treatment, the arginine, histidine, lysine, threonine and tyrosine moieties present in the antibody and/or fragment thereof which are not in active sites were protected from reaction, supplied as a conjugate together with an enzyme marker. A method according to claim 1 characterised in that the modification is carried out using a pyrocarbonate having the formula: R - O - CO - O - OC - O - R, where R is an alkyl, aryl or pyridyl group. A method according to claim 4 characterised in that the pyrocarbonate is diethylpyrocarbonate.

Inventors: DAWKES ADRIAN CHARLES, DIMENT JOHN ARTHUR, YEARWOOD GRAHAM DELISLE, DAWKES, ADRIAN CHARLES, DIMENT, JOHN ARTHUR, YEARWOOD, GRAHAM DELISLE
Applicants: ORTHO CLINICAL DIAGNOSTICS INC, ORTHO-CLINICAL DIAGNOSTICS, INC.
Application year: 1995
Main classification: G01N33
IPC codes: G01N33, C07K1, A61K39, C07K16